Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban dose-escalation and dose-confirmation study in acute coronary syndromes
2006-004449-40Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Rivaroxaban plus background antiplatelet therapy with Placebo plus background antiplatelet therapy (2 arms). Primary endpoint: Stage 1 dose-escalation primary endpoint. Started Nov 2006; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2006-004449-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004449-40.